Source: Annual Congress 2002 - Bronchial responsiveness, nebulization, devices and airway inflammation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
X. M. Zeng, M. Phelan, R. Crichton (London, United Kingdom; Waterford, Ireland). In vitro performance characteristics of a novel multi-dose dry powder inhaler Airmax™ at different inspiratory flow rates. Eur Respir J 2002; 20: Suppl. 38, 3353

Member's Comments

No comment yet.

Related content which might interest you: In vitro delivery of formoterol via a novel multi-dose dry powder inhaler, at clinically relevant inspiratory flow rates Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003 In vitro testing of two budesonide dry powder inhalers at different flow rates Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001 Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers Source: Eur Respir J 2001; 18: 780-783 Year: 2001 In vitro dosage emission for different flow rates from a combination of eformoterol and budesonide in a dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 Inspiratory profiles and consistency of behaviour regarding dose delivery characteristics of two dry powder inhalers in COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 13s Year: 2004 Peak inspiratory flow rates through placebo dry powder inhaler device in various asthma and COPD patients Source: Annual Congress 2012 - Asthma management Year: 2012 Measurement of inspiratory flow through 3 different dry powder inhalation devices using In-check in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 493s Year: 2001 Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001 Consider the turbulent energy not inhalation flow when patients use dry powder inhalers (DPIs) Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Peak inspiratory flow in COPD: implications for the use of dry powder inhalers Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 Assessment of peak inspiratory flow through dry powder inhalers in asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002 Peak inspiratory flow rates in COPD patients with Easyhaler® dry powder inhaler Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Performance characteristics of a multi dose dry powder inhaler (MDPI) with respect to the use of different deaggregation systems Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004 The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Peak inspiratory flow rate and the slope of the inhalation profile in dry powder inhalers (DPI) Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001 A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 The genuair® inhaler, a novel multidose dry powder inhaler, demonstrates consistent aerodynamic precision Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 In-use performance of sofotec´s dry powder inhaler Source: Eur Respir J 2004; 24: Suppl. 48, 584s Year: 2004 Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 Long-term preference and ease of use of a novel dry powder inhaler with budesonide in comparison to a conventional inhaler in asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 121s Year: 2001